Burcon NutraScience (BU) Q3 2025 earnings summary

Executive summary

• Achieved significant milestones, including a successful CAD 9.4 million rights offering and securing operational control of a U.S. production facility through an alliance with ProMan, enabling full-scale commercialization of the plant protein portfolio.

• Launched new products: sunflower isolate protein, next-generation Peazazz pea protein, and Puratein canola protein for egg replacement, all generating strong market interest.

• Established a global collaboration with Puratos to bring canola protein products to the baking industry.

• Over 100 customers evaluating products, with initial deliveries expected to include pea, hemp, and canola proteins.

Financial highlights

• Rights offering raised CAD 9.4 million, strengthening the balance sheet and supporting operations through to expected cash flow positivity in 2026.

• Generated $62,000 in revenue for the quarter, up from $0 in the same quarter last year, driven by protein isolate sales and contract research.

• Net loss narrowed to $1.8 million ($0.01 per share) from $2.0 million ($0.02 per share) year-over-year.

• Cash on hand is sufficient to support the company’s burn rate for at least the next two years.

• Gross R&D expenses decreased to $0.7 million from $1.0 million year-over-year.

Outlook and guidance

• Clear path to cash flow positive in 2026, with recurring revenue expected to begin in the second half of 2025.

• Facility acquisition expected to close soon, with commercial production of protein products targeted for the first half of 2025.

• Margin expansion anticipated quarter-on-quarter as production and sales scale.

• No major financings planned unless an opportunistic situation arises.

• Focus remains on production, sales, and establishing market leadership in protein innovation.